• / Free eNewsletters & Magazine
  • / My Account
Home>Dyax shares jump 40% on 'best-in-class' potential for new drug

Dyax shares jump 40% on 'best-in-class' potential for new drug

3party Content

Wed, 1 Apr 2015

By Russ Britt, MarketWatch Analyst says angioedema treatment could supplant others LOS ANGELES (MarketWatch) -- Positive results on early testing for an angiodema drug helped shoot shares of Dyax Corp. up more than 43% in after-hours trading Tuesday, as one analyst said the treatment could be "best
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.